What is Xencor?
Founded in 1997 and headquartered in Pasadena, California, Xencor Inc. is dedicated to pioneering innovative treatments through the development of engineered monoclonal antibodies and cytokine therapeutics. The company's focus on addressing critical unmet needs in oncology and autoimmune diseases positions it as a significant player in the biopharmaceutical sector. Xencor's strategic approach involves leveraging its proprietary protein engineering platform to create novel drug candidates with enhanced efficacy and safety profiles.
How much funding has Xencor raised?
Xencor has raised a total of $237.2M across 7 funding rounds:
Series B
$12.3M
Series C
$50M
Series D
$10M
Series E
$60M
Debt
$7.5M
Stock Offering
$72.4M
Share Placement
$25M
Series B (1999): $12.3M with participation from Stafford Capital Partners
Series C (2000): $50M led by Moore Capital, Stafford Capital Partners, and Sands Brothers Asset Management
Series D (2005): $10M supported by Zen Investments
Series E (2007): $60M featuring Zen Investments, Oxford Bioscience Partners, Novo Nordisk, Merlin Nexus, and MedImmune Ventures
Debt (2010): $7.5M, investors not publicly disclosed
Stock Issuance/Offering (2013): $72.4M, investors not publicly disclosed
Share Placement (2021): $25M, investors not publicly disclosed
Key Investors in Xencor
Oxford Bioscience Partners
Oxford Bioscience Partners is an international venture capital firm specializing in life science technology based investments, with offices in Boston, Massachusetts and Seoul, Korea.
MedImmune Ventures
MedImmune Ventures is a venture capital firm focused on investments in the biotechnology and pharmaceutical sectors.
Moore Capital
Moore Capital, LLC is committed to maximizing the value of its private equity investments and supporting partners through hard work, professional service, and confidentiality.
What's next for Xencor?
With a significant enterprise-level funding history and recent strategic backing, Xencor is poised for accelerated growth and clinical advancement. The company's trajectory suggests a focus on progressing its lead candidates through late-stage clinical trials and potentially towards commercialization. Future capital infusions or strategic partnerships may be anticipated as Xencor aims to expand its therapeutic offerings and solidify its market presence in the competitive biopharmaceutical landscape. The company's commitment to innovation in antibody and cytokine engineering will likely drive its future development.
See full Xencor company page
